NCT05571969终止1 期
A Phase Ib, Open Label, Multicenter Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 14
- 试验地点
- 5
- 主要终点
- Determination of the MTD of dovitinib given in combination with 2X-121 (MTD).
研究概览
简要总结
This is a Phase Ib, two-part, multi-center study. In Part 1, the study will evaluate the safety and tolerability, antitumor activity, pharmacokinetics, and determine the maximum tolerated dose (MTD) of 2X-121 monotherapy (at BID regimen) in patients with advanced solid tumors. In Part 2, the study will evaluate safety and tolerability, antitumor activity, pharmacokinetics and determine the MTD of dovitinib when given in combination with the MTD of 2X-121 determined in Part 1.
详细描述
Part 1
This part of the study will follow an accelerated titration method followed by a standard "3+3" design to determine the MTD of 2X-121. The MTD is defined as one dose level (cohort) below the dose in which dose limiting toxicities (DLTs) were observed in ≥ 33% of the participants.
The calculation of the sample size for this trial is based on the traditional 3 + 3 dose escalation scheme which is conducted as follows:
- Subjects are treated in cohorts of one (Cohort 1) or three (Cohorts 2-3) subjects, each receiving the same dose. For the assessment of a DLT, subjects are observed for 14 days.
- In Cohort 1, if the one subject does not exhibit a DLT, the next cohort of three subjects will receive the next higher dose (Cohort 2). In Cohort 2, if none of the three subjects exhibits a DLT, the next cohort of three subjects will receive the next higher dose (Cohort 3).
- Otherwise, if at least one subject of a cohort exhibits a DLT, a further cohort of three subjects is treated at the same dose level (cohort) without escalating the dose.
- If exactly one out of the six subjects treated at this dose exhibits a DLT, the trial continues as planned at the next higher dose level (cohort).
- If two or more subjects out of the six subjects treated at this dose exhibit a DLT, the dose escalation stops at that level and the next lower dose is considered as the MTD. When the escalation has stopped, additional subjects will be treated at the MTD to a total of six subjects.
Cohort escalation in Part 1 and Part 2 (i.e., the decision to progress from one cohort (dose level) to another) will not proceed until all of the following events have occurred:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older.
- •Histologically or cytological documented solid tumor.
- •Available tumor biopsy (most recent) for DRP® analysis.
- •Measurable disease by CT scan or MRI if possible.
- •Performance status of ECOG ≤
- •Recovered to Grade <1 or baseline from prior surgery or from acute toxicities of prior radiotherapy, or from treatment with cytotoxic, hormonal or biologic agents.
- •≥ 2 weeks must have elapsed since any prior surgery or therapy with G-CSF and GM-CSF.
- •Patients with intracranial disease must be on stable or decreased level of steroid therapy (e.g. dexamethasone) for at least 7 days prior to baseline MRI. Non-enzymatic inducing anti-epileptic drugs are allowed.
- •Adequate conditions as evidenced by the following clinical laboratory values:
- •Absolute neutrophils count (ANC) ≥ 1500/mm3 (1.5 x 10³/mL)
- •Hemoglobin > 10.0 g/dL
- •Platelets ≥ 100,000/mm3 (≥ 100 x 10⁹/L)
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN or ≤5x ULN in presence of liver metastases
- •Serum bilirubin ≤ 1.5 ULN
- •Alkaline phosphatase ≤ 2.5 x ULN
- •Creatinine ≤ 1.5 ULN
- •Blood urea nitrogen (BUN) ≤2X ULN.
- •Life expectancy equal or longer than 3 months.
- •The subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided and has had the opportunity to discuss the study with the investigator or designee.
- •The subject is able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study.
- •The subject is able to understand the nature of the study and any potential hazards associated with participating in it.
- •Negative pregnancy test for female subjects of childbearing potential. Women of childbearing potential (WOCBP) and Women of non-childbearing potential are eligible to participate. Both women of childbearing potential and women of non-childbearing potential should use an approved method of birth control and agree to continue to use this method for the duration of the study (and for 90 days after taking the last dose of study drug).
- •Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only) (e.g., diaphragm, cervical cap, male condom, and female condom and spermicidal foam, sponges, and film), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile for at least three months before screening or 2 years post-menopausal at time of screening. All male subjects/partners must agree to consistently and correctly use a condom for the duration of the study and for 90 days after taking the study drug. In addition, subjects may not donate sperm for the duration of the study and for 90 days after taking study drug.
排除标准
- •Concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period.
- •Other malignancy with exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to entering the study.
- •Any active infection requiring parenteral or oral antibiotic treatment.
- •History of coagulation or bleeding disorder or subject currently on therapeutic anticoagulant medication.
- •Note: Prophylactic doses of heparin or low molecular weight heparin are allowed.
- •Known HIV positivity.
- •Known active hepatitis B or C.
- •Clinically significant (i.e. active) cardiovascular disease:
- •Stroke within ≤ 6 months prior to day 1
- •Transient ischemic attack (TIA) within ≤ 6 months prior to day 1
- •Myocardial infarction within ≤ 6 months prior to day 1
- •Unstable angina
- •New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF)
- •Serious cardiac arrhythmia requiring medication.
- •Other medications or conditions, including surgery, that in the Investigator's opinion would contraindicate study participation for safety reasons or interfere with the interpretation of study results.
- •Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of 2X-121 and dovitinib.
- •Requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.
- •Female patients who are pregnant or breast-feeding (pregnancy test with a positive result before study entry).
结局指标
主要结局
Determination of the MTD of dovitinib given in combination with 2X-121 (MTD).
时间窗: Evaluated after up to approximately 2 years
To determine the MTD of dovitinib given in combination with 2X-121 (MTD) in patients with advanced solid tumors.
Determination of the MTD of 2X-121 monotherapy.
时间窗: Evaluated after up to approximately 2 years
To determine the maximum tolerated dose (MTD) of 2X-121 monotherapy given twice daily (BID) in patients with advanced solid tumors.
次要结局
- To evaluate the duration of overall response (DOR) of 2X-121 monotherapy (Part 1) and in combination with dovitinib (Part 2).(Evaluated after up to approximately 2 years)
- To evaluate progression free survival (PFS) of 2X-121 monotherapy (Part 1) and in combination with dovitinib (Part 2).(Evaluated after up to approximately 2 years)
- To evaluate overall survival (OS) of 2X-121 monotherapy (Part 1) and in combination with dovitinib (Part 2).(Evaluated after up to approximately 2 years)
- To evaluate the objective response rate (ORR) of 2X-121 monotherapy (Part 1) and in combination with dovitinib (Part 2).(Evaluated after up to approximately 2 years)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaNon-Hodgkin LymphomaNCT05950165Cho Pharma Inc.37
招募中
1 期
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid MalignanciesHead and Neck CancerEndometrial CancerTriple Negative Breast CancerSoft Tissue SarcomaNon Small Cell Lung CancerOvarian CancerMelanomaCervical CancerClassic Hodgkin LymphomaNasopharyngeal CarcinomaNCT05955105Innolake Biopharm200
终止
1 期
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)Small Cell Lung Cancer and Breast CancerNCT03773133Ipsen9
终止
1 期
A Study of MEK162 and AMG 479 in Patients With Selected Solid TumorsMetastatic Pancreatic AdenocarcinomaBRAF Mutated MelanomaNCT01562899Pfizer77
已完成
1 期
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid TumorsSolid TumorLung CancerHCCNCT04172506Akeso65